BPC-157 vs. TB-500 is not a choice of preference; it is a question of biomarker data. Clinical protocols should rely on specific mechanisms, not anecdotal reports. PeptidePanel maps lab results to the appropriate peptide targets. Data-driven. See the blog for more.
